| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We are interested in molecular mechanisms involved in the progression of castration-resistant prostate cancer (CRPC). We found significantly higher expression of miR-30d in the androgen-independent LNCaP-AI cell line compared with the androgen-dependent LNCaP cell line using miRNA microarrays and qPCR. Clinicopathological study revealed that miR-30d expression levels were significantly higher in bone metastatic CRPC tissue than in untreated primary prostate cancer tissue. To evaluate the biological functions of miR-30d during the progression of CRPC, we determined whether miR-30d overexpressing cell lines grew well without androgen, and thus manifest growth characteristics of CRPC. As shown by the cell proliferation assay, LNCaP-30d cell lines were able to grow in an androgen-indepleted medium, while the cotrol cell (LNCaP-C) grew poorly in the absence of androgen. Taken together, we found that miR-30d promotes prostate cancer cell proliferation in an androgen-indepleted.
|
